LLY · 8-K · 20260805PR000077
Revenue Performance and Mix
ELI LILLY & Co · 2026-08-05 · Importance 64 · Surprise 56 · From source text
Q2 2026 worldwide revenue increased 48% year over year to $22.974 billion, driven by a 60% increase in volume that was partly offset by a 13% decrease in realized prices.,Key Products revenue increased to $15.7 billion, with Mounjaro revenue rising 91% to $9.943 billion and Zepbound revenue rising 46% to $4.928 billion.,U.S. revenue increased 33% to $14.4 billion, while revenue outside the U.S. increased 80% to $8.6 billion.,Mounjaro and Zepbound together generated $14.871 billion, or approximately 65% of total Q2 revenue, compared with $8.580 billion in Q2 2025.
Key facts
- Q2 2026 revenue: $22,974 million, increased 48% compared with Q2 2025. source
- Q2 2026 worldwide revenue was $23.0 billion, an increase of 48% compared with Q2 2025, driven by a 60% increase in volume and a 13% decrease in realized prices. source
- Q2 2026 operating income was $8,978 million, a 31% increase versus prior year. source
- Jardiance revenue outside the U.S. included a sales-based milestone of $250 million in Q2 2026 associated with collaboration with Boehringer Ingelheim. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +37.5% | Q2 2026 revenue: $22,974 million, increased 48% compared with Q2 2025. |
| operating_income | positive | realized | +10.7% | Q2 2026 operating income was $8,978 million, a 31% increase versus prior year. |
| revenue | positive | realized | — | Q2 2026 worldwide revenue was $23.0 billion, an increase of 48% compared with Q2 2025, driven by a 60% increase in volume and a 13%… |
| revenue | negative | realized | — | Q2 2026 worldwide revenue was $23.0 billion, an increase of 48% compared with Q2 2025, driven by a 60% increase in volume and a 13%… |